Skip to content
GLP-1 Desk
Menu

Evidence review

Compounded vs Brand-Name GLP-1: How to Read the Trade-Off

Brand-name Wegovy and Zepbound are FDA-approved; compounded GLP-1 is not. Here is what that difference actually means for cost, access and safety.

By The Desk, Provider Intelligence Desk

Nearly every provider on our board sells one of two things: the brand-name drug — Wegovy or Zepbound, straight from the manufacturer — or a compounded version of the same active molecule, mixed by a pharmacy. They are not the same product, and the difference drives most of the price gap you see across the field. Here is how to read it.

What "brand-name" means

Wegovy is semaglutide 2.4 mg, approved by the FDA for chronic weight management in adults who meet the label's BMI criteria3. Zepbound is tirzepatide, approved on the same footing4. "FDA-approved" is a specific claim: the agency has reviewed the manufacturer's own clinical data and manufacturing process and cleared the exact product for sale. The efficacy figures the whole category advertises come from trials of these branded molecules — roughly 15% mean weight loss for semaglutide1 and up to about 21% for tirzepatide2.

What "compounded" means

A compounded GLP-1 is the same active ingredient prepared by a pharmacy rather than the drug's manufacturer. Critically, compounded drugs are **not** FDA-approved — the FDA does not review them for safety, effectiveness, or quality before they reach patients5. Compounding is legal and long-established, but it operates under a different regulatory frame: 503A pharmacies compound against individual prescriptions, while 503B outsourcing facilities register with the FDA and follow federal manufacturing standards6. We unpack that distinction, and how to vet a compounder, in is compounded GLP-1 legit and safe.

Why the price gap exists

The headline reason readers choose compounded is cost. Brand-name GLP-1 carries a manufacturer's list price; compounded versions typically undercut it by a wide margin. That gap is not a trick — it reflects the difference between a patented, FDA-reviewed product and a pharmacy-prepared one. What the gap does not tell you is anything about relative safety in your specific case, which is why the Desk never scores a provider up for being cheap alone.

How to choose between them

Reach for **brand-name** if:

- You want the exact product studied in the pivotal trials and reviewed by the FDA. - You have insurance coverage that narrows the price gap. - You prefer the manufacturer's pre-filled pen and standardized dosing.

Reach for **compounded** if:

- Out-of-pocket cost is the binding constraint and brand pricing is out of reach. - You have vetted the pharmacy — a named, LegitScript-verified operator, ideally a 503B facility. - You are comfortable with a product the FDA has not individually reviewed.

Most of our board is compounded-only, but a meaningful minority offer brand access — Ondra Health and Vaylen among them. If brand capability is your filter, start there and compare against the top-scored CoreAge Rx using our alternatives view.

The Desk's read

Neither route is universally "better." Brand-name buys you FDA review and trial-grade certainty; compounded buys you access at a price many patients can actually sustain. The wrong move is choosing compounded blind — from an anonymous pharmacy, on price alone. Vet the operator first, decide which molecule you want in our semaglutide vs tirzepatide guide, then use the full comparison desk to line up your finalists.

Frequently asked questions

Is compounded GLP-1 the same drug as Wegovy or Zepbound?

It uses the same active molecule — semaglutide or tirzepatide — but it is prepared by a pharmacy and is not FDA-approved. The FDA reviews the branded products for safety and effectiveness; it does not individually review compounded versions.

Why is compounded GLP-1 so much cheaper?

The price gap reflects the difference between a patented, FDA-reviewed manufacturer product and a pharmacy-prepared one. It is not evidence of a scam, but it also says nothing about relative safety in your case.

Which should I choose?

Choose brand-name for FDA review and trial-grade certainty, or coverage that narrows the cost gap. Choose compounded when out-of-pocket cost is the binding constraint and you have vetted a named, certified pharmacy.

References

  1. Wilding JPH, Batterham RL, Calanna S, et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). New England Journal of Medicine. https://pubmed.ncbi.nlm.nih.gov/33567185/
  2. Jastreboff AM, Aronne LJ, Ahmad NN, et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). New England Journal of Medicine. https://pubmed.ncbi.nlm.nih.gov/35658024/
  3. U.S. Food and Drug Administration (2021). Wegovy (semaglutide) injection — Prescribing Information. Drugs@FDA. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/215256s000lbl.pdf
  4. U.S. Food and Drug Administration (2023). Zepbound (tirzepatide) injection — Prescribing Information. Drugs@FDA. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/217806s000lbl.pdf
  5. U.S. Food and Drug Administration (2024). Compounding and the FDA: Questions and Answers. FDA.gov. https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers
  6. U.S. Food and Drug Administration (2024). Compounding Laws and Policies (Sections 503A and 503B). FDA.gov. https://www.fda.gov/drugs/human-drug-compounding/compounding-laws-and-policies

Medical disclaimer: This content is for general educational purposes only and is not medical advice, diagnosis, or treatment. Always consult a licensed healthcare professional before starting, stopping, or changing any treatment.